<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830283</url>
  </required_header>
  <id_info>
    <org_study_id>BJCDPC-8</org_study_id>
    <nct_id>NCT01830283</nct_id>
  </id_info>
  <brief_title>The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination</brief_title>
  <official_title>Phase 4 Study of the Varicella Vaccine After the 2nd Dose Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Center for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety, immunogenicity and immune effect of the Varicella vaccine after&#xD;
      the 2nd dose vaccination in Chao yang district, Bei jing, since the 2nd varicella vaccination&#xD;
      was promoted by Beijing Center for Disease Control and Prevention in November, 2012.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;Breakthrough&quot; varicella cases and varicella cases were monitored to evaluate the protective&#xD;
      effective in a large population.&#xD;
&#xD;
      Make the basic evaluation of safety for the two dose of varicella vaccination&#xD;
&#xD;
      Monitoring the Varicella virus origin and virus types from illness cases in Chao yang&#xD;
      district&#xD;
&#xD;
      Make the evaluation of healthy costs reduce for the varicella emergency vaccination after&#xD;
      large number of varicella cases occurred.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of varicella after 2 dose vaccination</measure>
    <time_frame>5 years</time_frame>
    <description>Detection the Varicella virus origin and virus types from illness cases in Chao yang district</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate of varicella vaccine after 2 dose injection</measure>
    <time_frame>5 years</time_frame>
    <description>Adverse event rate of varicella vaccine after 2 dose injection</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Antibody titre of varicella vaccine after 2 dose injection</measure>
    <time_frame>6 monthes</time_frame>
    <description>Antibody titre of varicella vaccine after 2 dose injection</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50000</enrollment>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>1 dose varicella vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The providers would get the 2nd dose since they had one dose varicella vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 dose varicella vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The provider never get the varicella vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>varicella vaccine</intervention_name>
    <description>The providers would get varicella vaccine</description>
    <arm_group_label>1 dose varicella vaccine</arm_group_label>
    <arm_group_label>2 dose varicella vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants were between 4-12 years old&#xD;
&#xD;
          -  Participants were in good healthy determined through medical history, physical&#xD;
             examination, clinical judgment of the investor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having a fever (axillary temperature &gt;37.0â„ƒ) before enrollment;&#xD;
&#xD;
          -  Having a disease history of seizures, brain and mental disease and the vaccination&#xD;
             history of allergies and convulsions;&#xD;
&#xD;
          -  Antibiotics allergy;&#xD;
&#xD;
          -  Having a problem of intramuscular injection because thrombocytopenia or other blood&#xD;
             coagulation disorder;&#xD;
&#xD;
          -  Having immunodeficiency or under immunosuppression therapy, radiation therapy;&#xD;
&#xD;
          -  Having respiratory diseases, acute infection, chronic disease and HIV infection;&#xD;
&#xD;
          -  Having systemic skin rash, skin tinea, herpes;&#xD;
&#xD;
          -  Chronic liver and kidney disease;&#xD;
&#xD;
          -  Heart disease, and severe hypertension;&#xD;
&#xD;
          -  Have received whole blood, plasma or immunoglobulin therapy 3 months before&#xD;
             enrollment;&#xD;
&#xD;
          -  Have not received other vaccination in 7 days before enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nianmin Shi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chaoyang District Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chaoyang District Centers for Disease Control and Prevention</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 3, 2013</study_first_submitted>
  <study_first_submitted_qc>April 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <last_update_submitted>May 27, 2013</last_update_submitted>
  <last_update_submitted_qc>May 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

